189 related articles for article (PubMed ID: 23161177)
1. Effect of topical pressure-lowering medication on prevention of intraocular pressure spikes after intravitreal injection.
El Chehab H; Le Corre A; Agard E; Ract-Madoux G; Coste O; Dot C
Eur J Ophthalmol; 2013; 23(3):277-83. PubMed ID: 23161177
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of prophylactic treatment of intraocular pressure spikes due to intravitreal injections].
El Chehab H; Le Corre A; Giraud JM; Ract-Madoux G; Swalduz B; Dot C
J Fr Ophtalmol; 2012 Oct; 35(8):614-21. PubMed ID: 22832030
[TBL] [Abstract][Full Text] [Related]
3. Effect of prophylactic medication and influence of vitreous reflux in pressure rise after intravitreal injections of anti-VEGF drugs.
Carnota-Méndez P; Méndez-Vázquez C; Otero-Villar J; Saavedra-Pazos JA
Eur J Ophthalmol; 2014; 24(5):771-7. PubMed ID: 24706353
[TBL] [Abstract][Full Text] [Related]
4. Effect of Dorzolamide/Timolol or Brinzolamide/Timolol prophylaxis on intravitreal anti-VEGF injection-induced intraocular hypertension.
Kim GN; Han YS; Chung IY; Seo SW; Park JM; Yoo JM
Semin Ophthalmol; 2013 Mar; 28(2):61-7. PubMed ID: 23448557
[TBL] [Abstract][Full Text] [Related]
5. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
[TBL] [Abstract][Full Text] [Related]
6. [Topical application of hypotensive drugs for the prevention of intraocular pressure elevation after intravitreal injections of anti-VEGF drugs].
Andreeva YS; Alkharki L; Shelankova AV; Budzinskaya MV
Vestn Oftalmol; 2024; 140(2. Vyp. 2):73-79. PubMed ID: 38739134
[TBL] [Abstract][Full Text] [Related]
7. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
Frenkel MP; Haji SA; Frenkel RE
Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
[TBL] [Abstract][Full Text] [Related]
8. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
[TBL] [Abstract][Full Text] [Related]
9. Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degeneration-the role of oral acetazolamide in protecting glaucoma patients.
Murray CD; Wood D; Allgar V; Walters G; Gale RP
Eye (Lond); 2014 Oct; 28(10):1218-22. PubMed ID: 25081290
[TBL] [Abstract][Full Text] [Related]
10. Effect of antiglaucoma agents on short-term intraocular pressure fluctuations after intravitreal bevacizumab injections.
Shoeibi N; Ghosi Z; Jafari H; Omidtabrizi A
Int Ophthalmol; 2021 Mar; 41(3):1081-1090. PubMed ID: 33389369
[TBL] [Abstract][Full Text] [Related]
11. [Current therapeutic possibilities for uveal ocular hypertension].
Belousova NIu
Vestn Oftalmol; 2014; 130(5):74-7. PubMed ID: 25711067
[TBL] [Abstract][Full Text] [Related]
12. Effect of prophylactic intraocular pressure-lowering medication (brinzolamide) on intraocular pressure after ranibizumab intravitreal injection: A case-control study.
Song S; Yu XB; Dai H
Indian J Ophthalmol; 2016 Oct; 64(10):762-766. PubMed ID: 27905340
[TBL] [Abstract][Full Text] [Related]
13. Fixed-combination brimonidine/timolol as adjunctive therapy to a prostaglandin analog: a 3-month, open-label, replacement study in glaucoma patients.
Nguyen QH; Earl M
J Ocul Pharmacol Ther; 2009 Dec; 25(6):541-4. PubMed ID: 20028261
[TBL] [Abstract][Full Text] [Related]
14. Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab.
Theoulakis PE; Lepidas J; Petropoulos IK; Livieratou A; Brinkmann CK; Katsimpris JM
Klin Monbl Augenheilkd; 2010 Apr; 227(4):280-4. PubMed ID: 20408074
[TBL] [Abstract][Full Text] [Related]
15. Diurnal intraocular pressure efficacy of the timolol-brimonidine fixed combination and the timolol-dorzolamide fixed combination as a first choice therapy in patients with pseudoexfoliation glaucoma.
Yüksel N; Gök M; Altıntaş O; Cağlar Y
Curr Eye Res; 2011 Sep; 36(9):804-8. PubMed ID: 21851166
[TBL] [Abstract][Full Text] [Related]
16. Hypotensive efficacy of topical brimonidine for intraocular pressure spikes following intravitreal injections of antivascular endothelial growth factor agents: a randomised crossover trial.
Felfeli T; Hostovsky A; Trussart R; Yan P; Brent MH; Mandelcorn ED
Br J Ophthalmol; 2019 Oct; 103(10):1388-1394. PubMed ID: 30573499
[TBL] [Abstract][Full Text] [Related]
17. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo P
Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma.
Lorenz K; Wasielica-Poslednik J; Bell K; Renieri G; Keicher A; Ruckes C; Pfeiffer N; Thieme H
PLoS One; 2017; 12(2):e0171636. PubMed ID: 28199397
[TBL] [Abstract][Full Text] [Related]
19. Comparison of ocular hypotensive actions of fixed combinations of brimonidine/timolol and dorzolamide/timolol.
García-Feijoó J; Sáenz-Francés F; Martínez-de-la-Casa JM; Méndez-Hernández C; Fernández-Vidal A; Calvo-González C; García-Sánchez J
Curr Med Res Opin; 2010 Jul; 26(7):1599-606. PubMed ID: 20429818
[TBL] [Abstract][Full Text] [Related]
20. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.
Hatanaka M; Reis A; Sano ME; Susanna R
J Glaucoma; 2010; 19(5):331-5. PubMed ID: 19730119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]